Drug or technology

Dabrafenib

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

MAR 26, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Tafinlar (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for labeling changes to an established BRAF inhibitor; does not report clinical trial outcomes or efficacy data.

Regulatory UpdateNovartis Dabrafenib